For example, the creation of a novel IL13 variant, termed IL13 (4MS) engineered to enhance selectivity for the IL13Rα2 receptor over IL13Rα1, has been incorporated into a bispecific CAR-T design which aimed to improve the efficacy of CAR-T cell therapy against glioblastoma (106). The gene discussed is IL13; the disease is glioblastoma.